SCHEMBL1406487

SCHEMBL1406487

COc1cc(C)c2cc(C(=O)NNC(=O)c3ccccc3)c(=O)oc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.56
RAB9A P51151 5/20 0.56
KDM4E B2RXH2 5/20 0.56
MAPT P10636 5/20 0.56
ALDH1A1 P00352 5/20 0.49
POLB P06746 1/20 0.49
MAOB P27338 5/20 0.47
MAOA P21397 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
GLA P06280 2/20 0.46
GAA P10253 2/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PLA2G1B P04054 1/20 0.44
PKM P14618 1/20 0.44
ALOX12 P18054 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1406230 0.89 MAPT (0.54) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL1406631 0.81 KDM4E (0.74) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL1406253 0.80 SLC16A3 (0.59) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL1406485 0.80 KDM4E (0.47) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL1406739 0.77 KDM4E (0.43) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL29968097 0.74 ALDH1A1 (0.66) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL52178 0.74 ALDH1A1 (0.66) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL14326164 0.73 MAOB (0.65) KDM4EMAPTALDH1A1MAOBMAOA
SCHEMBL13345862 0.72 NPC1 (1.00) NPC1RAB9AKDM4EMAPTALDH1A1
SCHEMBL13996204 0.72 ALDH1A1 (0.56) NPC1RAB9AKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2295053-B1 Novel 2H-chromen-2-one-3-carboxamides for medical uses INST MATERIA MEDICA CAMS (CN) 2016-10-19 EP disclosed
US-8338401-B2 Coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2012-12-25 US disclosed
EP-2295053-A1 Novel 2H-chromen-2-one-3-carboxamides for medical uses THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2011-03-16 EP disclosed
WO-2008013928-A2 TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR BIOGEN IDEC MA INC. (US) 2008-01-31 WO disclosed
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-07-06 US disclosed
EP-1570846-A1 THE NOVEL COUMARIN-AMIDE DERIVATIVES AND ITS PREPARATION, SAID DRUG COMPOSITION AND ITS USE THE INSTITUTE OF MATERIA MEDICA OF CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148834-A1 Novel coumarin-amide derivatives and its preparation, said drug composition and its use INSR, GLS, INSRR NPC1 574/4885RAB9A 4207/4885KDM4E 2436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.